产品详情
产品名称JI-101
简述Inhibitors
纯化99.00%
生物活性JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4). JI-101 inhibits angiogenesis, and subsequently tumor growth.
基因/蛋白名称Ephrin Receptor inhibitor; PDGFR inhibitor; VEGFR inhibitor
CAS号900573-88-8
计算分子量466.339
配方C22H20BrN5O2
保存3 years -20˚C powder;2 years -80˚C in solvent;
产品描述
Research Area:Cardiovascular
SMILES:COC1=C(C=C(C=C1)Br)NC(=O)NC2=CC=CC3=C2C=CN3CC4=CC(=NC=C4)N
Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
Receptor:Ephrin Receptor; PDGFR; VEGFR
Boling pt:
Melting pt:
Solubility:DMSO: 10 mM
Appearance:
Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.
背景文献
1.Mark L. Wade, Neeraj Agarwal et al. A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Investigational New Drugs, December 2015, Volume 33, Issue 6, pp 1217-1224
The lead time is currently 7-30 days.
